[go: up one dir, main page]

WO2006021874A8 - Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer - Google Patents

Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer

Info

Publication number
WO2006021874A8
WO2006021874A8 PCT/IB2005/002560 IB2005002560W WO2006021874A8 WO 2006021874 A8 WO2006021874 A8 WO 2006021874A8 IB 2005002560 W IB2005002560 W IB 2005002560W WO 2006021874 A8 WO2006021874 A8 WO 2006021874A8
Authority
WO
WIPO (PCT)
Prior art keywords
prostate cancer
markers
diagnosis
assays
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2005/002560
Other languages
French (fr)
Other versions
WO2006021874A2 (en
WO2006021874A3 (en
Inventor
Dvir Dahary
Sarah Pollock
Zurit Levine
Rotem Sorek
Michal Ayalon-Soffer
Pinchas Akiva
Amir Toporik
Osnat Sella-Tavor
Shirley Sameah-Greenwald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compugen USA Inc
Original Assignee
Compugen USA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compugen USA Inc filed Critical Compugen USA Inc
Priority to EP05805032A priority Critical patent/EP1735468A2/en
Priority to CA002554707A priority patent/CA2554707A1/en
Priority claimed from US11/043,806 external-priority patent/US7368548B2/en
Publication of WO2006021874A2 publication Critical patent/WO2006021874A2/en
Anticipated expiration legal-status Critical
Publication of WO2006021874A8 publication Critical patent/WO2006021874A8/en
Publication of WO2006021874A3 publication Critical patent/WO2006021874A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel markers for prostate cancer that are both sensitive and accurate. Furthermore, these markers are able to distinguish between prostate cancer and benign prostate hyperplasia ('BPH'). These markers are overexpressed in prostate cancer specifically, as opposed to normal prostate tissue and/or BPH. The measurement of these markers, alone or in combination, in patient samples provides information that the diagnostician can correlate with a probable diagnosis of prostate cancer. The markers of the present invention, alone or in combination, show a high degree of differential detection between prostate cancer and non-cancerous states.
PCT/IB2005/002560 2004-01-27 2005-01-27 Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer Ceased WO2006021874A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP05805032A EP1735468A2 (en) 2004-01-27 2005-01-27 Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer
CA002554707A CA2554707A1 (en) 2004-01-27 2005-01-27 Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer

Applications Claiming Priority (46)

Application Number Priority Date Filing Date Title
US53912904P 2004-01-27 2004-01-27
US53912804P 2004-01-27 2004-01-27
US60/539,129 2004-01-27
US60/539,128 2004-01-27
US58416604P 2004-07-01 2004-07-01
US60/584,166 2004-07-01
US60725904P 2004-09-07 2004-09-07
US60/607,259 2004-09-07
US62087404P 2004-10-22 2004-10-22
US62091804P 2004-10-22 2004-10-22
US62065604P 2004-10-22 2004-10-22
US62067704P 2004-10-22 2004-10-22
US62091604P 2004-10-22 2004-10-22
US62085304P 2004-10-22 2004-10-22
US60/620,656 2004-10-22
US60/620,677 2004-10-22
US60/620,918 2004-10-22
US60/620,874 2004-10-22
US60/620,853 2004-10-22
US60/620,916 2004-10-22
US62113104P 2004-10-25 2004-10-25
US60/621,131 2004-10-25
US62810104P 2004-11-17 2004-11-17
US62816704P 2004-11-17 2004-11-17
US62813404P 2004-11-17 2004-11-17
US62812304P 2004-11-17 2004-11-17
US62811204P 2004-11-17 2004-11-17
US62815604P 2004-11-17 2004-11-17
US62825104P 2004-11-17 2004-11-17
US62823104P 2004-11-17 2004-11-17
US62811104P 2004-11-17 2004-11-17
US62817804P 2004-11-17 2004-11-17
US62814504P 2004-11-17 2004-11-17
US60/628,251 2004-11-17
US60/628,112 2004-11-17
US60/628,101 2004-11-17
US60/628,167 2004-11-17
US60/628,123 2004-11-17
US60/628,231 2004-11-17
US60/628,145 2004-11-17
US60/628,156 2004-11-17
US60/628,178 2004-11-17
US60/628,134 2004-11-17
US11/043,806 US7368548B2 (en) 2004-01-27 2005-01-27 Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer
US11/043,806 2005-01-27
US- 2008-09-12

Publications (3)

Publication Number Publication Date
WO2006021874A2 WO2006021874A2 (en) 2006-03-02
WO2006021874A8 true WO2006021874A8 (en) 2007-03-15
WO2006021874A3 WO2006021874A3 (en) 2009-04-09

Family

ID=35967908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/002560 Ceased WO2006021874A2 (en) 2004-01-27 2005-01-27 Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of prostate cancer

Country Status (1)

Country Link
WO (1) WO2006021874A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902921A (en) * 1997-01-31 1999-05-11 Pioneer Hi-Bred International, Inc. Hybrid maize plant and seed (34K77)
KR101008758B1 (en) * 2001-09-18 2011-01-14 제넨테크, 인크. Methods for Diagnosing and Treating Tumors and Compositions for the Same
WO2003105758A2 (en) * 2002-06-12 2003-12-24 Avalon Pharmaceuticals, Inc. Cancer-linked gene as target for chemotherapy

Also Published As

Publication number Publication date
WO2006021874A2 (en) 2006-03-02
WO2006021874A3 (en) 2009-04-09

Similar Documents

Publication Publication Date Title
Pirsaheb et al. Current advances of carbon dots based biosensors for tumor marker detection, cancer cells analysis and bioimaging
Chan et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients
ES2522542T3 (en) Neoplasia detection from a stool sample
Cho et al. Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients
EP1712639A1 (en) Method for the diagnosis of cancer by detecting circulating DNA and RNA
Crocitto et al. Prostate cancer molecular markers GSTP1 and hTERT in expressed prostatic secretions as predictors of biopsy results
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
ES2533428T3 (en) Use of DPPIV / Seprase as a marker for cancer
WO2005072049A3 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of endometriosis
WO2006012646A3 (en) Amacr cancer markers
AU2010200755A1 (en) Biomarker panel for colorectal cancer
WO2002061128A3 (en) Method of determining a chemotherapeutic regimen based on ercc1 expression
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
AU2002303444A1 (en) Detection of microsatellite instability and its use in diagnosis of tumors
WO2006015312A3 (en) Prognosis of breast cancer patients
WO2009007958A3 (en) Compositions, methods and kits for the diagnosis of carriers of mutations in the brca1 and brca2 genes and early diagnosis of cancerous disorders associated with mutations in brca1 and brca2 genes
WO2002064015A8 (en) Pin1 as a marker for prostate cancer
Hellwinkel et al. Methylation of the TPEF‐and PAX6‐promoters is increased in early bladder cancer and in normal mucosa adjacent to pTa tumours
WO2004062487A3 (en) Methods of detecting gene expression in normal and cancerous cells
DE60318294D1 (en) Detection of invasive cancer induced by HPV and its precursor lesions with invasive potential
Passerotti et al. Urinary hyaluronan as a marker for the presence of residual transitional cell carcinoma of the urinary bladder
Zeng et al. A simple and smart AND-gate DNA nanoprobe for correlated enzymes tracking and cell-selective imaging
Trabulsi et al. Development of a voided urine assay for detecting prostate cancer non‐invasively: a pilot study
WO2006038089A3 (en) Method for identification of neoplastic transformation with particular reference to prostate cancer
MX2007008984A (en) Cancer markers and detection methods.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2554707

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005276208

Country of ref document: AU

NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

ENP Entry into the national phase in:

Ref document number: 2005276208

Country of ref document: AU

Date of ref document: 20050127

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005276208

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005805032

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005805032

Country of ref document: EP